Fundraising Fox

Caldera Therapeutics, Inc.

Cambridge, US · Founded 2025 · Delaware corporation · 3 known investors

Biotech

Founders & leadership

PT
Praveen TipirneniExecutive

Board

MD
Michelle DoiginBoard directorPartner at Omega Funds
AR
Aaron RoystonBoard director
MGMichael Gladstone
Michael Gladstonein𝕏Board directorPartner at Atlas Venture
XS
Xiaodi SuBoard director

Investors · 3

Atlas VenturereportedCambridge · $500K – $1Mvia Michael Gladstone · board
Omega FundsreportedBostonvia Michelle Doig · board
venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$37.5M disclosed across 1 round · 2026

▶$37.5MraisedJan 2026 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michelle DoigDirector
  • Aaron RoystonDirector
  • Michael GladstoneDirector
  • Xiaodi SuDirector
  • Praveen TipirneniExecutive Officer, Director
Offering amount
$37.5M
Amount sold
$37.5M
First sale
Jan 2026
Incorporated
Corporation, Delaware, 2025
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Synlogic (SYBX) Merger with Caldera Therapeutics Signals Market Skepticism Amid High Price-to-Salesgurufocus.com · Jul 2026Caldera Therapeutics, Inc. entered into an agreement and plan of merger to acquire Synlogic, Inc. in a reverse merger transaction. | MarketScreenermarketscreener.com · Jul 2026Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placementbusinesswire.com · Jul 2026Caldera Therapeutics raises USD112.5M to advance novel IBD treatments | HealthCare Middle East & Africa - No.1 Health & Pharma Manufacturing Industry Publicationhealthcaremea.com · Jan 2026Caldera Therapeutics Launches with $112.5M in Total Capitalfinsmes.com · Jan 2026Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Diseasebusinesswire.com · Jan 2026

Frequently asked questions

Who are Caldera Therapeutics, Inc.'s investors?
Caldera Therapeutics, Inc.'s investors include Atlas Venture, Omega Funds, venBio Global Strategic.
How much funding has Caldera Therapeutics, Inc. raised?
Caldera Therapeutics, Inc. has disclosed $37.5M raised across 1 round.
Where is Caldera Therapeutics, Inc. headquartered?
Caldera Therapeutics, Inc. is headquartered in Cambridge, US.